Precision oncology startup 4baseCare has raised ₹90 crore (around $9.8 million) in the first close of its Series B round, co-led by investors Ashish Kacholia and Lashit Sanghvi, with participation from existing backer Yali Capital.
The funding comes after a two-year gap since the company’s $6 million Series A round in 2024, which was led by Yali Capital with participation from Infosys.
Expansion and Product Roadmap
4baseCare said the fresh capital will be used to expand its hospital-linked genomics laboratory network across India, the Middle East, Southeast Asia, Latin America and Central Asia. The company will also invest in scaling OncoTwin, its AI-powered precision oncology platform that supports clinicians in cancer diagnosis and treatment selection.
OncoTwin integrates genomic testing with clinical and outcomes data to assist oncologists with evidence-based, population relevant treatment decisions.
Business Model and Differentiation
Founded by Hitesh Goswami, 4baseCare focuses on building clinico genomic datasets tailored to underrepresented populations, addressing gaps in cancer research that are often skewed toward Western cohorts.
The company works directly with hospitals to embed genomics-led cancer diagnostics within clinical workflows, enabling real-world data collection alongside routine care. This approach allows the platform to generate actionable insights that are more relevant to emerging markets.
Global Recognition
4baseCare’s OncoTwin platform was recently selected for the MSK iHub Program at Memorial Sloan Kettering Cancer Center, providing further validation of its clinical and technological approach.
Rising Investor Interest in Oncology
Investor interest in oncology-focused startups has gained momentum in recent years. In 2024, Everhope Oncology raised $10 million in seed funding, while MOC Cancer Care & Research Centre secured $18 million led by Elevation Capital. Other funded players include ErlySign, OnCare and OneCell Diagnostics.
Why It Matters
As cancer incidence rises across emerging markets, platforms like 4baseCare that combine genomics, AI and real-world clinical data are increasingly seen as critical to improving outcomes. The Series B infusion positions the company to scale internationally while deepening its role in precision oncology for non-Western populations.
Follow Startupbydoc for daily startup insights, funding news, IPO analysis, and business breakdowns.